The BioHub - by Avetix

We were delighted to welcome Daniel Fero, Managing Director of OMX Ventures, onto the Biohub. He's working at the intersection of science, startups, and investment — where breakthrough research meets real-world impact. Daniel Fero is a venture investor focused on biotech and life sciences, with experience spanning early-stage company building and healthcare innovation. Based in the Greater Bos...

In todays episode we talk about Dan's career and the work Pelage are doing, leading innovation in the hair loss space.

In this episode of The BioHub Podcast , Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma. Jeremy’s career spans roles at Genentech, Opsona, and Inflazome, which was acquired by Roche before stepping into the CEO role at Poolbeg, a public biotech taking a different approach to drug development. In this conversation, we talk about how Poolbeg is building a more capita...

Today’s guest is Ashley Zehnder, the co-founder and CEO of Fauna Bio—a pioneering biotech company unlocking insights from the natural world to transform human health. With a background in genomics and a passion for translating cutting-edge science into real-world therapies, Ashley is leading a new frontier in drug discovery—one that looks to nature’s own evolutionary experiments to uncover novel t...

In this episode of The BioHub Podcast , Max sits down with Robert Jacks, President and CEO of Sparrow Pharmaceuticals. Robert brings more than 25 years of experience in biotech, having founded or co-founded multiple companies and raised over $300 million across his career. From roles in corporate development at Pfizer to leading companies through development, approval, and exit, he’s seen the indu...

In this episode, we’re joined by Jenny Yang, Founder and CEO of Outpost Bio, a company building an AI-driven platform to understand how the human microbiome interacts with drugs, food, and other interventions. Jenny shares her journey from machine learning and genomics research through to her PhD at the University of Oxford and experience at Exscientia, before founding Outpost Bio. We discuss why...

In this episode of The BioHub Podcast , Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals. Cary’s career spans finance, M&A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder. In this conversation, Cary shares his...

Today’s guest brings one of the broadest and most thoughtful perspectives in neuroscience, spanning clinical practice, drug development, investing, and company building. Dr. Spyros Papapetropoulos is a neurologist, neuroscientist, and biotech leader who has spent his career at the intersection of science, medicine, and innovation. With deep experience across both large pharma and emerging biotech,...

Today’s guest brings a rare blend of medicine, science, and strategy to the frontlines of biotech innovation. Dr. Megan McGill is a physician-scientist and biotech leader with over two decades of experience spanning clinical medicine, neuroscience research, and drug development. Trained as both an MD and PhD, her work has focused deeply on understanding the brain—particularly the mechanisms behind...

In this episode of The Biohub Podcast, Amber sits down with Tess Bevers CEO and Founder of Novogaia, a company combining AI and mass spectrometry to discover new drug molecules from fungi. We explore why fungi remain one of the most underexplored sources of chemistry in nature, the historical bottlenecks in natural product drug discovery, and how new advances in AI are helping researchers prioriti...

Welcome to another episode of The BioHub . Today I’m joined by Jason Tardio —COO of Immunic Therapeutics, a clinical stage biotech for oral small molecule therapies for chronic inflammatory and autoimmune diseases. In this episode we explore Jason's awesome background, from starting as a sales rep and climbing the ladder into his position today, as COO.

Welcome to another episode of The BioHub . Today I’m joined by Steffen-Sebastian Bolz — scientist, physician, entrepreneur, and Co-Founder of Aphaia Pharma , a clinical-stage biotech developing precision-targeted drug formulations to treat and prevent metabolic disorders like obesity and prediabetes. We’ll be talking about the science behind Aphaia, why they’re not building with an exit in mind, a...

In this episode of The BioHub Podcast , Max sits down with Dr. Philippe Chambon , CEO and Co-Founder of EG 427. After more than 30 years in pharma and venture capital — raising over $1 billion to back life science companies — Philippe has made the move from investor to operator, now leading EG 427. The company is pioneering a new approach to neurological disease with pinpoint DNA medicine , design...

Today’s guest is Dr. Yerem Yeghiazarians — a leading interventional cardiologist, professor of medicine at the University of California, San Francisco, and a physician-scientist working at the cutting edge of cardiovascular innovation. With medical training from Johns Hopkins and advanced cardiology specialization at Brigham and Women’s Hospital, Dr. Yeghiazarians has spent over two decades at UCS...

In this episode of The BioHub Podcast , Max sits down with Amit Etkin , Founder and CEO of Alto Neuroscience. Psychiatry is one of the few areas in medicine still dominated by trial and error. Amit is trying to change that. A trained psychiatrist and neuroscientist, Amit founded Alto to bring precision medicine into mental health — using biomarkers to better match patients with the treatments that...

We were delighted to be joined by James Kim (Chief Corporate Officer) and Ronald Li (Chief Executive Officer), at Medera Biopharmaceuticals. Medera is a company at the forefront of pharmaceutical innovation, focused on advancing next-generation therapies and building a globally competitive platform across research, development, and commercialization. As the industry continues to evolve — driven by...

On this episode we welcome Cellares' co-founder, Fabian Gerlinghaus, to discuss their revolutionary, fully automated, cell therapy manufacturing platform. Cell therapies work - the science is proven. Fabian & the team's mission is to deliver these life-changing therapies at scale, to change more patient's lives. On this episode we talk through Fabian's background in robotics, h...

Today, we’re joined by Dipal Doshi, a leader at theforefront of modern biotechnology and rare disease innovation. As CEO of Entrada Therapeutics, Dipal has helped build the company from its earliest days into a clinical-stage pioneer focused on unlocking intracellular therapies. With a career that spans investment banking at MerrillLynch, global pharma at Eli Lilly and Company, and senior leadersh...

In this episode of The BioHub Podcast , Max sits down with Barry Quart , CEO of Connect Biopharma and one of the most experienced biotech leaders in the industry. Barry’s career spans more than three decades across biotech and pharma, including founding Ardea Biosciences (acquired by AstraZeneca) and leading Heron Therapeutics, where he helped bring multiple drugs through development and approval....

Today’s guest is Robert Clarke, the CEO of Kinaset — acompany at the forefront of next-generation therapeutics and biotechnology innovation. Robert brings a unique blend of scientific curiosity, strategic leadership, and entrepreneurial drive to the biotech world. With a background spanning life sciences, investment, and company building, he has spent much of his career working at the intersection...

The biggest bottleneck in drug development is no longer discovery, it's in the clinic. Formation Bio's proprietary AI-native platform is changing drug development to bring new treatments to patients faster and more efficiently. We catch up with Emily Gransky, who is shaping the talent strategy behind one of biotechs most exciting stories. Emily previously shaped Flagship & RA Ventures...

Ann is the Founder and CEO of Rejuvenate Biomed , a clinical-stage biotechnology company developing combination therapies aimed at targeting the biological mechanisms behind age-related diseases. With more than two decades of experience in pharmaceutical research and development, she has built a career focused on translating cutting-edge science into therapies that can improve patients’ lives. Bef...

In this episode of The BioHub, I’m joined by Catherine Isted, Chief Financial Officer of Santhera Pharmaceuticals. Catherine’s career journey is a unique one, from starting as a bench scientist, to nearly two decades in healthcare investment banking, and now leading finance at multiple biotech companies. In this International Women’s Day special, we talk about her path through the industry, the im...

Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes. Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expan...

We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub . Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema. Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak...